
What is claimed is:

1. Use of a therapeutically effective amount of at least one compound of formula (I):




(I), and

a therapeutically effective amount of at least one panitumumab compound chosen from panitumumab, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing or

a therapeutically effective amount of at least one cetuximab compound chosen from cetuximab, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing in the manufacture of a medicament for treating cancer in a subject, wherein the subject is a subject whose cancer progressed on at least one prior anti-EGFR therapy.


2. Use of a therapeutically effective amount of at least one compound of formula (I):



(I)

in the manufacture of a medicament for resensitizing a subject to anti-EGFR therapy, wherein the subject is a subject whose cancer progressed on at least one anti-EGFR therapy.

3. Use of a therapeutically effective amount of at least one compound of formula (I):



(I), and

(a) a therapeutically effective amount of at least one panitumumab compound chosen from panitumumab, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing;

(b) a therapeutically effective amount of at least one cetuximab compound chosen from cetuximab, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing;

(c) a therapeutically effective amount of at least one capecitabine compound chosen from capecitabine, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing;

(d) a therapeutically effective amount of at least one regorafenib compound chosen from regorafenib, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing; or


(e) a therapeutically effective regimen of FOLFOX

in the manufacture of a medicament for simultaneously

(i) inhibiting, reducing, and/or diminishing survival and/or self-renewal cancer stem cells and

(ii) inhibiting, reducing, and/or diminishing survival and/or proliferation of heterogeneous cancer cells.


4. Use of a therapeutically effective amount of at least one compound of formula (I):



(I), and

a therapeutically effective amount of at least one capecitabine compound chosen from capecitabine, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing in the manufacture of a medicament for treating cancer in a subject, wherein the subject is a subject whose cancer progressed on at least one prior capecitabine therapy.


5. Use of a therapeutically effective amount of at least one compound of formula (I):



(I)

in the manufacture of a medicament for resensitizing a subject to capecitabine therapy, wherein the subject is a subject whose cancer progressed on at least one prior capecitabine therapy.

6. Use of a therapeutically effective amount of at least one compound of formula (I):




(I), and

a therapeutically effective amount of at least one regorafenib compound chosen from regorafenib, pharmaceutically acceptable salts thereof, and solvates of any of the

foregoing in the manufacture of a medicament for treating cancer in a subject, wherein the subject is a subject whose cancer progressed on at least one prior regorafenib therapy.


7. Use of a therapeutically effective amount of at least one compound of formula (I):



(I)

in the manufacture of a medicament for resensitizing a subject to regorafenib therapy, wherein the subject is a subject whose cancer progressed on at least one prior regorafenib therapy.


8. Use of a therapeutically effective amount of at least one compound of formula (I):



(I), and

a therapeutically effective regimen of FOLFOX in the manufacture of a medicament for treating cancer in a subject, wherein the subject is a subject whose cancer progressed on at least one prior FOLFOX therapy.


9. Use of a therapeutically effective amount of at least one compound of formula (I):



(I)

in the manufacture of a medicament for resensitizing a subject to FOLFOX therapy, wherein the subject is a subject whose cancer progressed on at least one prior FOLFOX therapy.

10. The use according to any one of claims 1-9 and 23-24, wherein the at least one compound of formula (I) is chosen from compounds having formula (I)



(I)

prodrugs, derivatives, pharmaceutically acceptable salts of any of the foregoing, and solvates of any of the foregoing.

11. The use according to claim 3 or 23, wherein the medicament comprises a therapeutically effective amount of at least one capecitabine compound chosen from capecitabine, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, and a therapeutically effective amount of at least one oxaliplatin compound chosen from oxaliplatin, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing.

12. The use according to claim 4, wherein the medicament further comprises a therapeutically effective amount of at least one oxaliplatin compound chosen from oxaliplatin, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing.

13. The use according to claim 3 or 23, wherein the medicament comprises a therapeutically effective regimen of FOLFOX and a therapeutically effective amount of at least one angiogenesis inhibitor.

14. The use according to claim 8, wherein the medicament further comprises a therapeutically effective amount of at least one angiogenesis inhibitor.

15. The use according to claim 13 or 14, wherein the at least one angiogenesis inhibitor is chosen from bevacizumab, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing.

16. The use according to any one of claims 1, 2, or 4-9, wherein the subject's cancer is associated with an aberrant Stat3 pathway.

17. The use according to claim 3, 23, or 24, wherein the differentiated tumor cells are from a cancer associated with an aberrant Stat3 pathway.

18. The use according to claim 16 or 17, wherein the cancer associated with an aberrant Stat 3 pathway is chosen from colon adenocarcinoma, rectal adenocarcinoma, gastroesophageal junction adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, esophageal adenocarcinoma, cholangiocarcinoma, hepatocellular carcinoma, and colorectal cancer.


19. The use according to claim 18, wherein the cancer associated with an aberrant Stat 3 pathway is advanced, metastatic, unresectable, or recurrent.

20. The use according to any one of claims 1-9 and 23-24, wherein the at least one compound of formula (I) is present at a dose of about 480 mg, about 960 mg, or about 1000 mg.

21. The use according to claim 20, wherein the at least one compound of formula (I) is to be administered in a divided dose.

22. The use according to an one of claims 1-9 and 23-24, wherein the at least one compound of formula (I) is present at a dose of about 240 mg twice daily, about 480 mg twice daily, or about 500 mg.

23. Use of a therapeutically effective amount of at least one compound of formula (I):



(I), and

(a) a therapeutically effective amount of at least one panitumumab compound chosen from panitumumab, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing;

(b) a therapeutically effective amount of at least one cetuximab compound chosen from cetuximab, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing;

(c) a therapeutically effective amount of at least one capecitabine compound chosen from capecitabine, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing;

(d) a therapeutically effective amount of at least one regorafenib compound chosen from regorafenib, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing; or

(e) a therapeutically effective regimen of FOLFOX

in the manufacture of a medicament for treating cancer in a subject.

24. The use according to claim 23, wherein the cancer is cancer is advanced, metastatic, unresectable, recurrent, or/and refractory.